Achillion Reports Second Quarter 2017 Financial Results And Proof-Of-Concept With A First-In-Class, Oral Factor D Inhibitor

Published: Aug 09, 2017

NEW HAVEN, Conn., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2017. For the second quarter of 2017, Achillion reported a net loss of $22.5 million or $0.16 per share, compared with a net loss of $18.5 million or $0.14 per share for the second quarter of 2016. Cash, cash equivalents, marketable securities, and interest receivable as of June 30, 2017 were $369.9 million.

Back to news